6

Шизофрения —это серьёзное расстройство психики планетарного масштаба, которым страдает около 1% населения, существенно влияя на социальные аспекты бытия человека и профессиональную деятельность. Характеризуетсяпатологическими симптомами: бредовыми идеями, галлюцинациями зрительного или слухового характера, глубоким нарушением поведенческих реакций и когнитивной дисфункцией в виде амнестии. Обычно дебют заболевания приходится на молодые годы

  • Ўқишлар сони 6
  • Нашр санаси 01-02-2025
  • Мақола тилиRus
  • Саҳифалар сони214-223
Русский

Шизофрения —это серьёзное расстройство психики планетарного масштаба, которым страдает около 1% населения, существенно влияя на социальные аспекты бытия человека и профессиональную деятельность. Характеризуетсяпатологическими симптомами: бредовыми идеями, галлюцинациями зрительного или слухового характера, глубоким нарушением поведенческих реакций и когнитивной дисфункцией в виде амнестии. Обычно дебют заболевания приходится на молодые годы

№ Ҳавола номи
1 1.Meltzer, H. Y., & Stahl, S. M. (1976). The dopamine hypothesis of schizophrenia: a review. Schizophrenia bulletin, 2(1), 19.2.Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. (1991). Dopamine in schizophrenia: a review and reconceptualization. The American journal of psychiatry, 148(11), 1474-1486.3.Simpson, E. H., Kellendonk, C., & Kandel, E. (2010). A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron, 65(5), 585-596.4.Grace, A. A. (2016). Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nature Reviews Neuroscience, 17(8), 524-532.5.Floresco, S. B., Todd, C. L., & Grace, A. A. (2001). Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. Journal of Neuroscience, 21(13), 4915-4922.6.Lodge, D. J., & Grace, A. A. (2006). The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology, 31(7), 1356-1361.7.Heckers, S., & Konradi, C. (2015). GABAergic mechanisms of hippocampal hyperactivity inschizophrenia. Schizophrenia research, 167(1-3), 4-11.8.Benes, F. M., McSparren, J., Bird, E. D., SanGiovanni, J. P., & Vincent, S. L. (1991). Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Archives of general psychiatry, 48(11), 996-1001.9.Thompson, M., Weickert, C. S., Wyatt, E., & Webster, M. J. (2009). Decreased glutamic acid decarboxylase67 mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. Journal of psychiatric research, 43(11), 970-977.10.Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., ... & Lewis, D. A. (2003). Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. Journal of Neuroscience, 23(15), 6315-6326.11.Carlen, M., Meletis, K., Siegle, J. H., Cardin, J. A., Futai, K., Vierling-Claassen, D., ... & Tsai, L. H. (2012). A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Molecular psychiatry, 17(5), 537-548.12.Del Pino, I., García-Frigola, C., Dehorter, N., Brotons-Mas, J. R., Alvarez-Salvado, E., de Lagrán, M. M., ... & Rico, B. (2013). Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes. Neuron, 79(6), 1152-1168.13.Sohal, V. S., Zhang, F., Yizhar, O., & Deisseroth, K. (2009). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature, 459(7247), 698-702.14.Lewis, D. A., Curley, A. A., Glausier, J. R., & Volk, D. W. (2012). Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in neurosciences, 35(1), 57-67.15.Dallérac G, Li X, Lecouflet P, Morisot N, Sacchi S, Asselot R et al. Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine. Proc Natl Acad Sci U S A 2021; 118(23).16.Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annual review of neuroscience 2009; 32: 267–287.] 17.Clarkson RL, Liptak AT, Gee SM, Sohal VS, Bender KJ. D3 Receptors Regulate Excitability in a Unique Class of Prefrontal Pyramidal Cells. J Neurosci 2017; 37(24): 5846–5860.18.Sanoev Z.I., Mirzaev Yu.R. Pharmacological Activity Of The Possessing New Atypical Neuroleptics 1-Phenyltetrahydroisoquinoline Structure. The American Journal of Medical Sciences and Pharmaceutical Research Published: August 11, 2020 | Pages: 18-26 Doi: https://doi.org/10.37547/TAJMSPR/Volume02Issue08-0319.Sanoev, Z.I., Mirzaev, Y.R. Research of a new atypical neuroleptic 1-(3,4,-methylenedioxyphenyl)-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline on the central nervous system. Annals of the Romanian Society for Cell Biology,2021,25(2), 2363–236920.Mirzaev, Y. R., Zhurakulov, S. N., Sanoev, Z. I., Vinogradova, V. I., & Sagdullayev, S. S. (2020). Atypical neuroleptic property of 1-phenyltetrahydroisoquinoline structure. Uz. Patent, 6321(10).21.Мирзаев Ю.Р., Саноев З.И., Жўрақулов Ш.Н., Виноградова В.И. Психофармакологические свойства производного тетрагидроизохинолина. Международный научный журнал “Unity of Science” Вена, Австрия, 2015, с. 170-174 22.Саноев З.И., Мирзаев Ю.Р., Якубова Л.К. Сравнительного фармакологического свойства производного тетрагидроизохинолина и седуксена. Новый день в медицине. Научно –реферативный, духовно-просветительский журнал. 2 (30/2) 2020, с. 365-36823.Zafar I. Sanoev. (2022). Study of acute toxicity and psychopharmacological activity of 1-(2-hydroxyphenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline. Oriental Journal of Medicine and Pharmacology, 2(02), 65–71. https://doi.org/10.37547/supsci-ojmp-02-02-08 24.Zafar I. Sanoev, & Yuriy R. Mirzaev (2022). Experimental study of the psychopharmacological activity of 1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline. Oriental Journal of Medicine and Pharmacology, 2(03), 32–40. https://doi.org/10.37547/supsci-ojmp-02-03-0525.Rakhimboev, S. D., et al. "Screening Study of the Anxiolytic Activity of New Triazole Compounds." Texas Journal of Medical Science13 (2022): 43-46.26.Rakhimboev S.D., et al. (2022). Screening study of neurotropic properties of new triazole derivative. Oriental Journal of Medicine and Pharmacology, 2(04), 12–20. https://doi.org/10.37547/supsci-ojmp-02-04-0227.Rahimboev, S., & Sanoev, Z. (2024). Neuropsychotropic activity of 1,2,4-triazole derivatives. Oriental Journal of Medicine and Pharmacology, 4(05), 12–26. https://doi.org/10.37547/supsci-ojmp-04-05-0228.Рахимбоев, С. Д. У., & Саноев, З. И. (2024). Противосудорожные препараты третьего поколения: фармакодинамика, фармакокинетика и применение. Re-healthjournal, (3 (23)), 37-46.29.SanoevZ.I., IsmailovaD.S., RakhimboevS.D., TolibovichT.T., ElmuradovB.J., AbdinazarovI.T., RashidovS.Z. (2023). Synthesis And Research Anticonvulsant Activity Of Annulated Triazolo-thiadiazine Derivative In Laboratory Animals. Biomedical & Pharmacology Journal. Vol. 16(4), p. 2457-2467.30.Arnold SJ, Ivleva EI, Gopal TA, Reddy AP, Jeon-Slaughter H, Sacco CB et al. Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer). Schizophr Bull 2015; 41(1): 233–249.31.Bobilev A. M., Perez J. M., Tamminga C. A. Molecular alterations in the medial temporal lobe in schizophrenia //Schizophrenia research. –2020. –Т. 217. –С. 71-85.32.Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1998; 1(4): 318–323.33.Li W, Ghose S, Gleason K, Begovic A, Perez J, Bartko J et al. Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia. Am J Psychiatry 2015; 172(4): 373–382.34.Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006; 188: 510–518.35.Tamminga CA, Stan AD, Wagner AD. The hippocampal formation in schizophrenia. Am J Psychiatry 2010; 167(10): 1178–1193.36.Brown RW, Varnum CG, Wills LJ, Peeters LD, Gass JT. Modulation of mGlu5 improves sensorimotor gating deficits in rats neonatally treated with quinpirole through changes in dopamine D2 signaling. Pharmacol Biochem Behav 2021; 211: 173292.37.Yan L, Shamir A, Skirzewski M, Leiva-Salcedo E, Kwon OB, Karavanova I et al. Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders. Mol Psychiatry 2018; 23(5): 1233–1243.38.Didriksen M, Fejgin K, Nilsson SR, Birknow MR, Grayton HM, Larsen PHet al. Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice. J Psychiatry Neurosci 2017; 42(1): 48–58.39.Heidbreder CA, Foxton R, Cilia J, Hughes ZA, Shah AJ, Atkins A et al. Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation. Psychopharmacology (Berl) 2001; 156(2–3): 338–351.
Кутилмоқда